This research article addresses the complexities of analytical process development and optimization in line with the principles set out in the Commission's Effectiveness of the Requirements for Medicinal Products for Human Use (ICH) Q14 guidelines. Focusing on the pharmaceutical and chemical industry, this article describes the early stages of development in terms of sustainable lifestyles. The first study explores the important role of analytical procedures in ensuring product quality and regulatory compliance, introduces ICH Q14 and explains its scope and objectives. The fundamental principles of audit development are reviewed in depth, including risk assessment, design, and the interaction between Audit Objectives (ATP) and Methodology. Operational Development Region (MODR). Concepts such as Design of Operations (DoE) and Quality by Design (QbD) are under scrutiny for their development and optimization. Real-life case studies demonstrate the application of Q14 principles and demonstrate successful examples of effective methods and continuous improvement in drug screening, drug purity testing and environmental analysis. Looking ahead, this article explores how new technologies, potentially innovative regulations and international cooperation will shape the development landscape. Challenges such as the complexity of new compounds and the need for sustainable practices are addressed and the need for business professionals to be flexible and innovative is emphasized. In summary, this research article can serve as a general guide for professionals in the pharmaceutical and chemical industry, providing insight into the content, eight owners, and use of development analysis. Using the principles defined in ICH Q14, community auditors can investigate the changing landscape and make further progress on quality assurance.